Jefferies cuts Boston Scientific stock price target on growth outlook By Investing.com

Boston Scientific beat first-quarter sales and EPS at $5.20 billion and $0.80 versus consensus of $5.17 billion and $0.79, but it cut 2026 organic growth guidance to 6.5%-8% from 10%-11% and EPS guidance to $3.34-$3.41 from $3.43-$3.49. Jefferies lowered its price target to $100 from $110 while keeping a Buy rating, citing weaker urology, cardiac rhythm management, and Watchman trends. The company also announced a $2 billion share repurchase program, partially offsetting the more cautious outlook.

Analysis

The market is reacting less to the quarter than to the reset in the slope of the earnings trajectory. In med-tech, valuation compression usually overshoots when a company goes from “can compound” to “can compound, but at a lower base,” because investors re-rate the long-duration cash flow stream before the actual EPS revisions fully flow through Street models. That makes BSX vulnerable to a second leg of de-rating if management keeps framing 10%+ growth as an upside case rather than a core case.

The bigger issue is not the absolute guide cut; it’s the signal that multiple product cycles are de-synchronizing at once. When urology, CRM, and Watchman all soften together, the market starts discounting a portfolio problem rather than a temporary execution hiccup, which typically takes 2-3 quarters to repair even if end demand stabilizes. Buybacks help near term, but they also can be read as an admission that incremental reinvestment opportunities are not being sourced with the same confidence.

The contrarian setup is that the selloff may already be pricing in a more permanent structural slowdown than the data support. A PEG near 0.55 is often what you see when the market is extrapolating the guidance reset too far into the out-years; if the company can show even modest sequential improvement in the pressured franchises, the stock can re-rate quickly because expectations are now low enough that a 1-2 point improvement in organic growth can drive a large multiple response. The near-term catalyst path is therefore less about this quarter and more about whether the next guidance update confirms stabilization versus a second downward reset.

Competitively, the beneficiaries are likely the faster-growing peers in electrophysiology, CRM, and continence/urology adjacencies that can use BSX’s stumble to reinforce share gains in salesforce coverage and hospital contracting. The second-order risk for BSX is that once distributor and physician behavior shifts, share losses can persist longer than the underlying demand weakness, making the recovery path months longer than management is implying.

Key Decisions for Investors

• Short BSX via call spreads into the next earnings/guide update; thesis is another 5-10% downside if management confirms that the growth reset is structural rather than transitory.
• Pair trade: long larger-quality med-tech names with cleaner execution profiles against short BSX over the next 1-2 quarters; this isolates idiosyncratic guidance risk while keeping sector beta neutral.
• If holding BSX long-term, hedge with near-dated puts around the next guidance event; implied vol should remain bid, making downside protection relatively efficient versus cashing out the core position.
• Look for a long entry only after two sequential evidence points of stabilization in the pressured franchises; reward improves if the stock bases for several weeks because the current multiple already discounts a meaningful portion of the reset.
• Use the buyback announcement as support, not a primary bull case: any rally on repurchase headlines should be sold into unless organic growth inflects first.